RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
Scope of the Report:
RNAi for Therapeutic is in the development stage and there is no use in the market. The fastest research is Clinical phrase III, Such as QP1-1007, QO1-1002 of Quark Pharmaceuticals. The major technology of RNAi for Therapeutic is siRNA, miRNA and shRNA. SiRNA technology is the most popular, with the expenses market share of 85%, following SiRNA, miRNA is the second of 16% expenses market share in 2015.
At present, global expenses concentrates in US and Europe, US takes 80% market share and Europe takes 5% market share. There is A Few R & D Company in the world and the market concentration is high. The top5 (expenses in RNAi for Therapeutic) companies are Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics. The five companies occupy about 83% of the market share.
The global RNAi for Therapeutic market is valued at 990 million USD in 2018 and is expected to reach 3580 million USD by the end of 2024, growing at a CAGR of 24.0% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of RNAi for Therapeutic.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the RNAi for Therapeutic market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the RNAi for Therapeutic market by product type and applications/end industries.
Market Segment by Companies, this report covers
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
siRNA
miRNA
shRNA
Market Segment by Applications, can be divided into
Cancer
Cardiovascular
HBV
Other
Table of Contents
1 RNAi for Therapeutic Market Overview
1.1 Product Overview and Scope of RNAi for Therapeutic
1.2 Classification of RNAi for Therapeutic by Types
1.2.1 Global RNAi for Therapeutic Revenue Comparison by Types (2019-2024)
1.2.2 Global RNAi for Therapeutic Revenue Market Share by Types in 2018
1.2.3 siRNA
1.2.4 miRNA
1.2.5 shRNA
1.3 Global RNAi for Therapeutic Market by Application
1.3.1 Global RNAi for Therapeutic Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Cancer
1.3.3 Cardiovascular
1.3.4 HBV
1.3.5 Other
1.4 Global RNAi for Therapeutic Market by Regions
1.4.1 Global RNAi for Therapeutic Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) RNAi for Therapeutic Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) RNAi for Therapeutic Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) RNAi for Therapeutic Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) RNAi for Therapeutic Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) RNAi for Therapeutic Status and Prospect (2014-2024)
1.5 Global Market Size of RNAi for Therapeutic (2014-2024)
2 Manufacturers Profiles
2.1 Alnylam Pharmaceuticals
2.1.1 Business Overview
2.1.2 RNAi for Therapeutic Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.2 Arbutus Biopharma (Tekmira)
2.2.1 Business Overview
2.2.2 RNAi for Therapeutic Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.3 Arrowhead
2.3.1 Business Overview
2.3.2 RNAi for Therapeutic Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.4 Dicerna Pharmaceuticals
2.4.1 Business Overview
2.4.2 RNAi for Therapeutic Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.5 Mirna Therapeutics
2.5.1 Business Overview
2.5.2 RNAi for Therapeutic Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.6 Quark Pharmaceuticals
2.6.1 Business Overview
2.6.2 RNAi for Therapeutic Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.7 RXi Pharmaceuticals
2.7.1 Business Overview
2.7.2 RNAi for Therapeutic Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.8 Silence Therapeutics
2.8.1 Business Overview
2.8.2 RNAi for Therapeutic Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.9 Benitec Biopharma
2.9.1 Business Overview
2.9.2 RNAi for Therapeutic Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.10 miRagen Therapeutics
2.10.1 Business Overview
2.10.2 RNAi for Therapeutic Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.11 Sylentis
2.11.1 Business Overview
2.11.2 RNAi for Therapeutic Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.12 Gradalis
2.12.1 Business Overview
2.12.2 RNAi for Therapeutic Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.13 Sirnaomics
2.13.1 Business Overview
2.13.2 RNAi for Therapeutic Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
2.14 Silenseed
2.14.1 Business Overview
2.14.2 RNAi for Therapeutic Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
3 Global RNAi for Therapeutic Market Competition, by Players
3.1 Global RNAi for Therapeutic Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 RNAi for Therapeutic Players Market Share
3.2.2 Top 10 RNAi for Therapeutic Players Market Share
3.3 Market Competition Trend
4 Global RNAi for Therapeutic Market Size by Regions
4.1 Global RNAi for Therapeutic Revenue and Market Share by Regions
4.2 North America RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
4.3 Europe RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
4.5 South America RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
5 North America RNAi for Therapeutic Revenue by Countries
5.1 North America RNAi for Therapeutic Revenue by Countries (2014-2019)
5.2 USA RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
5.3 Canada RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
5.4 Mexico RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
6 Europe RNAi for Therapeutic Revenue by Countries
6.1 Europe RNAi for Therapeutic Revenue by Countries (2014-2019)
6.2 Germany RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
6.3 UK RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
6.4 France RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
6.5 Russia RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
6.6 Italy RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
7 Asia-Pacific RNAi for Therapeutic Revenue by Countries
7.1 Asia-Pacific RNAi for Therapeutic Revenue by Countries (2014-2019)
7.2 China RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
7.3 Japan RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
7.4 Korea RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
7.5 India RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
8 South America RNAi for Therapeutic Revenue by Countries
8.1 South America RNAi for Therapeutic Revenue by Countries (2014-2019)
8.2 Brazil RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
8.3 Argentina RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
8.4 Colombia RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue RNAi for Therapeutic by Countries
9.1 Middle East and Africa RNAi for Therapeutic Revenue by Countries (2014-2019)
9.2 Saudi Arabia RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
9.3 UAE RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
9.4 Egypt RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
9.5 Nigeria RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
9.6 South Africa RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
10 Global RNAi for Therapeutic Market Segment by Type
10.1 Global RNAi for Therapeutic Revenue and Market Share by Type (2014-2019)
10.2 Global RNAi for Therapeutic Market Forecast by Type (2019-2024)
10.3 siRNA Revenue Growth Rate (2014-2024)
10.4 miRNA Revenue Growth Rate (2014-2024)
10.5 shRNA Revenue Growth Rate (2014-2024)
11 Global RNAi for Therapeutic Market Segment by Application
11.1 Global RNAi for Therapeutic Revenue Market Share by Application (2014-2019)
11.2 RNAi for Therapeutic Market Forecast by Application (2019-2024)
11.3 Cancer Revenue Growth (2014-2019)
11.4 Cardiovascular Revenue Growth (2014-2019)
11.5 HBV Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global RNAi for Therapeutic Market Size Forecast (2019-2024)
12.1 Global RNAi for Therapeutic Market Size Forecast (2019-2024)
12.2 Global RNAi for Therapeutic Market Forecast by Regions (2019-2024)
12.3 North America RNAi for Therapeutic Revenue Market Forecast (2019-2024)
12.4 Europe RNAi for Therapeutic Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific RNAi for Therapeutic Revenue Market Forecast (2019-2024)
12.6 South America RNAi for Therapeutic Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa RNAi for Therapeutic Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure RNAi for Therapeutic Picture
Table Product Specifications of RNAi for Therapeutic
Table Global RNAi for Therapeutic and Revenue (Million USD) Market Split by Product Type
Figure Global RNAi for Therapeutic Revenue Market Share by Types in 2018
Figure siRNA Picture
Figure miRNA Picture
Figure shRNA Picture
Table Global RNAi for Therapeutic Revenue (Million USD) by Application (2014-2024)
Figure RNAi for Therapeutic Revenue Market Share by Applications in 2018
Figure Cancer Picture
Figure Cardiovascular Picture
Figure HBV Picture
Figure Other Picture
Table Global Market RNAi for Therapeutic Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America RNAi for Therapeutic Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe RNAi for Therapeutic Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific RNAi for Therapeutic Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America RNAi for Therapeutic Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa RNAi for Therapeutic Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global RNAi for Therapeutic Revenue (Million USD) and Growth Rate (2014-2024)
Table Alnylam Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Alnylam Pharmaceuticals RNAi for Therapeutic Type and Applications
Table Alnylam Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Arbutus Biopharma (Tekmira) Basic Information, Manufacturing Base and Competitors
Table Arbutus Biopharma (Tekmira) RNAi for Therapeutic Type and Applications
Table Arbutus Biopharma (Tekmira) RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Arrowhead Basic Information, Manufacturing Base and Competitors
Table Arrowhead RNAi for Therapeutic Type and Applications
Table Arrowhead RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Dicerna Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Dicerna Pharmaceuticals RNAi for Therapeutic Type and Applications
Table Dicerna Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Mirna Therapeutics Basic Information, Manufacturing Base and Competitors
Table Mirna Therapeutics RNAi for Therapeutic Type and Applications
Table Mirna Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Quark Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table Quark Pharmaceuticals RNAi for Therapeutic Type and Applications
Table Quark Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table RXi Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table RXi Pharmaceuticals RNAi for Therapeutic Type and Applications
Table RXi Pharmaceuticals RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Silence Therapeutics Basic Information, Manufacturing Base and Competitors
Table Silence Therapeutics RNAi for Therapeutic Type and Applications
Table Silence Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Benitec Biopharma Basic Information, Manufacturing Base and Competitors
Table Benitec Biopharma RNAi for Therapeutic Type and Applications
Table Benitec Biopharma RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table miRagen Therapeutics Basic Information, Manufacturing Base and Competitors
Table miRagen Therapeutics RNAi for Therapeutic Type and Applications
Table miRagen Therapeutics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Sylentis Basic Information, Manufacturing Base and Competitors
Table Sylentis RNAi for Therapeutic Type and Applications
Table Sylentis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Gradalis Basic Information, Manufacturing Base and Competitors
Table Gradalis RNAi for Therapeutic Type and Applications
Table Gradalis RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Sirnaomics Basic Information, Manufacturing Base and Competitors
Table Sirnaomics RNAi for Therapeutic Type and Applications
Table Sirnaomics RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Silenseed Basic Information, Manufacturing Base and Competitors
Table Silenseed RNAi for Therapeutic Type and Applications
Table Silenseed RNAi for Therapeutic Revenue, Gross Margin and Market Share (2017-2018)
Table Global RNAi for Therapeutic Revenue (Million USD) by Players (2014-2019)
Table Global RNAi for Therapeutic Revenue Share by Players (2014-2019)
Figure Global RNAi for Therapeutic Revenue Share by Players in 2017
Figure Global RNAi for Therapeutic Revenue Share by Players in 2018
Figure Global Top 5 Players RNAi for Therapeutic Revenue Market Share in 2018
Figure Global Top 10 Players RNAi for Therapeutic Revenue Market Share in 2018
Figure Global RNAi for Therapeutic Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global RNAi for Therapeutic Revenue (Million USD) by Regions (2014-2019)
Table Global RNAi for Therapeutic Revenue Market Share by Regions (2014-2019)
Figure Global RNAi for Therapeutic Revenue Market Share by Regions (2014-2019)
Figure Global RNAi for Therapeutic Revenue Market Share by Regions in 2018
Figure North America RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Europe RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure South America RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Table North America RNAi for Therapeutic Revenue by Countries (2014-2019)
Table North America RNAi for Therapeutic Revenue Market Share by Countries (2014-2019)
Figure North America RNAi for Therapeutic Revenue Market Share by Countries (2014-2019)
Figure North America RNAi for Therapeutic Revenue Market Share by Countries in 2018
Figure USA RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Canada RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Mexico RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Table Europe RNAi for Therapeutic Revenue (Million USD) by Countries (2014-2019)
Figure Europe RNAi for Therapeutic Revenue Market Share by Countries (2014-2019)
Figure Europe RNAi for Therapeutic Revenue Market Share by Countries in 2018
Figure Germany RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure UK RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure France RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Russia RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Italy RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Table Asia-Pacific RNAi for Therapeutic Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific RNAi for Therapeutic Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific RNAi for Therapeutic Revenue Market Share by Countries in 2018
Figure China RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Japan RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Korea RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure India RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Southeast Asia RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Table South America RNAi for Therapeutic Revenue by Countries (2014-2019)
Table South America RNAi for Therapeutic Revenue Market Share by Countries (2014-2019)
Figure South America RNAi for Therapeutic Revenue Market Share by Countries (2014-2019)
Figure South America RNAi for Therapeutic Revenue Market Share by Countries in 2018
Figure Brazil RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Argentina RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Colombia RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Table Middle East and Africa RNAi for Therapeutic Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa RNAi for Therapeutic Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa RNAi for Therapeutic Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa RNAi for Therapeutic Revenue Market Share by Countries in 2018
Figure Saudi Arabia RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure UAE RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Egypt RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure Nigeria RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Figure South Africa RNAi for Therapeutic Revenue and Growth Rate (2014-2019)
Table Global RNAi for Therapeutic Revenue (Million USD) by Type (2014-2019)
Table Global RNAi for Therapeutic Revenue Share by Type (2014-2019)
Figure Global RNAi for Therapeutic Revenue Share by Type (2014-2019)
Figure Global RNAi for Therapeutic Revenue Share by Type in 2019
Table Global RNAi for Therapeutic Revenue Forecast by Type (2019-2024)
Figure Global RNAi for Therapeutic Market Share Forecast by Type (2019-2024)
Figure Global siRNA Revenue Growth Rate (2014-2019)
Figure Global miRNA Revenue Growth Rate (2014-2019)
Figure Global shRNA Revenue Growth Rate (2014-2019)
Table Global RNAi for Therapeutic Revenue by Application (2014-2019)
Table Global RNAi for Therapeutic Revenue Share by Application (2014-2019)
Figure Global RNAi for Therapeutic Revenue Share by Application (2014-2019)
Figure Global RNAi for Therapeutic Revenue Share by Application in 2019
Table Global RNAi for Therapeutic Revenue Forecast by Application (2019-2024)
Figure Global RNAi for Therapeutic Market Share Forecast by Application (2019-2024)
Figure Global Cancer Revenue Growth Rate (2014-2019)
Figure Global Cardiovascular Revenue Growth Rate (2014-2019)
Figure Global HBV Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Figure Global RNAi for Therapeutic Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global RNAi for Therapeutic Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global RNAi for Therapeutic Revenue Market Share Forecast by Regions (2019-2024)
Figure North America RNAi for Therapeutic Revenue Market Forecast (2019-2024)
Figure Europe RNAi for Therapeutic Revenue Market Forecast (2019-2024)
Figure Asia-Pacific RNAi for Therapeutic Revenue Market Forecast (2019-2024)
Figure South America RNAi for Therapeutic Revenue Market Forecast (2019-2024)
Figure Middle East and Africa RNAi for Therapeutic Revenue Market Forecast (2019-2024)
The Whole Body Cooling Therapeutic System Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscap...
Executive Summary
Azoth Analytics has released a research report titled "Global Therapeutic Antibody Market (2023 Edition)" which provides a complete analysis of the Global Therapeutic Antibody industry in terms of market segmentation By Product Type (Monoclonal Antibody, Bispecific Ant...
Asia Pacific biopharmaceuticals market will grow by 10.3% annually with a total addressable market cap of $1,776.7 billion over 2024-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discove...
Europe biopharmaceuticals market was valued at $116.5 billion in 2023 and will grow by 8.6% annually over 2023-2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing clinical t...
North America biopharmaceuticals market is projected to grow by 8.4% annually in the forecast period and reach $407.2 billion by 2033, driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, ...
Global biopharmaceuticals market will reach $1,001.1 billion by 2033, growing by 8.8% annually over 2023-2033. The growth is driven by the prevalence of chronic diseases along with aging population, rising investments in novel biopharma drugs, technological advancement for drug discovery, growing cl...
Overview of the Global Virtual Therapeutic Services Market:
The report discusses everything a marketer requires before investing in the global Virtual Therapeutic Services Market during the forecast period 2023-2030...
Asia Pacific small molecule API market will grow by 8.7% annually with a total addressable market cap of over $1 trillion over 2023-2032, driven by the increasing incidences of diseases, the development of high-potency small molecule APIs, patents expiry of the top-selling pharmaceuticals, the incre...
Europe small molecule API market was valued at $43.5 billion in 2022 and will grow by 7.4% annually over 2022-2032, driven by the increasing incidences of diseases, the development of high-potency small molecule APIs, patents expiry of the top-selling pharmaceuticals, the increasing technological de...
North America small molecule API market is projected to grow by 5.3% annually in the forecast period and reach $112.5 billion by 2032, driven by the increasing incidences of diseases, the development of high-potency small molecule APIs, patents expiry of the top-selling pharmaceuticals, the increasi...